CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapyAmelie Franken, Diether Lambrechts, Thomas Van Brussel et al.|Immunity|2024Cited by 108
The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patientsAnna C. H. Willemsen, Annemie M.W.J. Schols, Nina De Moor et al.|Cancer Medicine|2022Cited by 24
Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinomaMichel Bila, Paul M. Clément, Amelie Franken et al.|Oral Oncology|2023Cited by 13
A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck CancerMichel Bila, Paul M. Clément, Jeroen Van Dessel et al.|Frontiers in Oncology|2022Cited by 7
Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironmentFrancesca Lodi, Diether Lambrechts, Sam Vanmassenhove et al.|Cell Reports Medicine|2025Cited by 7